Ignite Creation Date:
2024-05-06 @ 7:46 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02596334
Status:
TERMINATED
Last Update Posted:
2018-11-13
First Post:
2015-10-16
Brief Title:
Study to Evaluate the Efficacy of MONotherapy of TiviCAY Versus a Triple Therapy in HIV-1-infected Patients
Sponsor:
Centre Hospitalier Régional dOrléans
Organization:
Centre Hospitalier Régional dOrléans
Study Overview
Official Title:
Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy Tivicay Versus the Maintenance of a Successful Triple Therapy Using Abacavir Lamivudine Dolutegravir Triumeq in HIV-1- Infected Patients
Status:
TERMINATED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
5 patients on tivicay had virological failure
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MONCAY
Brief Summary:
Triple antiretroviral regimens have greatly improved the prognosis of patients living with HIV PLHIV Patients virologically controlled and having a good immune restoration can have a life expectancy close or equal to that of people not infected with HIV1 However this is under the condition of a lifetime maintenance of an undetectable plasma viral load pVL 50 cpml On the other hand it is well established that aging increases comorbidities among PLHIV and the burden of co-medications2 This also has the consequence of frequent drug-drug interactions In this context it is important to decrease pills burden side-effects and drug-drug interactions while maintaining undetectability
Currently there is a strong interest for medical research to validate lightened regimens ie bithérapies 3-7 and monothérapies 89 particularly in a maintenance strategy with the primary objective of reducing burden of pills and side effects Several monotherapy trials using a boosted protease inhibitor PIr showed high level of viral suppression even if this proportion was not always non-inferior to maintaining a triple therapy 89 Fortunately when virological failure occurred under monotherapy virologic suppression was easily restored by the addition of two NRTI Patients who are most likely to maintain viral suppression under a reduced scheme are those that have a high nadir 100 CD4 mm3 no previous AIDS event and a sustained virologic suppression 12 months
Monotherapy is the option that best reduces the burden of pills and the risk of side effects or drug-drug interactions It must be considered using very powerful molecule that harbor a strong binding to its ligand in order to minimize the risk of selecting resistant mutants in the case of virologic failure To be as simple as possible in its use it must be a single agent administered as a single dose once a day and not boosted if possible The molecule must have very good tolerance Finally to be effective in viral sanctuaries this molecule should have a good or sufficient diffusion to ensure effective Cmin on wild viral strains Dolutegravir meets all these exigences10 In addition our team recently presented results of a pilot study showing that the switch of a successful combined antiretroviral regimen to dolutegravir monotherapy maintained undetectable viral load 20 cpml after a median of 7 months range 65-10 months
Currently there is a strong interest for medical research to validate lightened regimens ie bithérapies 3-7 and monothérapies 89 particularly in a maintenance strategy with the primary objective of reducing burden of pills and side effects Several monotherapy trials using a boosted protease inhibitor PIr showed high level of viral suppression even if this proportion was not always non-inferior to maintaining a triple therapy 89 Fortunately when virological failure occurred under monotherapy virologic suppression was easily restored by the addition of two NRTI Patients who are most likely to maintain viral suppression under a reduced scheme are those that have a high nadir 100 CD4 mm3 no previous AIDS event and a sustained virologic suppression 12 months
Monotherapy is the option that best reduces the burden of pills and the risk of side effects or drug-drug interactions It must be considered using very powerful molecule that harbor a strong binding to its ligand in order to minimize the risk of selecting resistant mutants in the case of virologic failure To be as simple as possible in its use it must be a single agent administered as a single dose once a day and not boosted if possible The molecule must have very good tolerance Finally to be effective in viral sanctuaries this molecule should have a good or sufficient diffusion to ensure effective Cmin on wild viral strains Dolutegravir meets all these exigences10 In addition our team recently presented results of a pilot study showing that the switch of a successful combined antiretroviral regimen to dolutegravir monotherapy maintained undetectable viral load 20 cpml after a median of 7 months range 65-10 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None